Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

0GP7

Medivir Ab (0GP7)

Medivir Ab
から:
次の項目別のソート:
 Showing the most relevant articles for your search:LSE:0GP7
日付受信時刻ニュースソース見出しコード企業名
2024/01/1516 : 45PR Newswire (US)Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostroxLSE:0GP7Medivir Ab
2024/01/0416 : 47PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyLSE:0GP7Medivir Ab
2023/12/1916 : 54PR Newswire (US)Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development planLSE:0GP7Medivir Ab
2023/12/1319 : 12PR Newswire (US)Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approvalLSE:0GP7Medivir Ab
2023/12/0620 : 20PR Newswire (US)Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runwayLSE:0GP7Medivir Ab
2023/12/0616 : 44PR Newswire (US)Medivir to present at the Carlsquare Equity Research Investor DayLSE:0GP7Medivir Ab
2023/12/0119 : 32PR Newswire (US)Bulletin from Extraordinary General Meeting in Medivir AB (publ)LSE:0GP7Medivir Ab
2023/11/2717 : 52PR Newswire (US)Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCCLSE:0GP7Medivir Ab
2023/11/2216 : 46PR Newswire (US)Medivir to present at the Redeye Life Science DayLSE:0GP7Medivir Ab
2023/11/2116 : 48PR Newswire (US)Medivir to present at the Erik Penser Bank Company EventLSE:0GP7Medivir Ab
2023/11/1317 : 49PR Newswire (US)Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDALSE:0GP7Medivir Ab
2023/11/0805 : 50PR Newswire (US)Notice of Extraordinary General Meeting in Medivir AB (publ)LSE:0GP7Medivir Ab
2023/10/2716 : 01PR Newswire (US)MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2023LSE:0GP7Medivir Ab
2023/10/2515 : 46PR Newswire (US)Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on FridayLSE:0GP7Medivir Ab
2023/10/2315 : 48PR Newswire (US)Nomination Committee of Medivir appointedLSE:0GP7Medivir Ab
2023/10/2022 : 29PR Newswire (US)Change in Medivir's Board of DirectorsLSE:0GP7Medivir Ab
2023/05/1701 : 38PR Newswire (US)Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023LSE:0GP7Medivir Ab
2023/05/0423 : 55PR Newswire (US)Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)LSE:0GP7Medivir Ab
2023/05/0423 : 25PR Newswire (US)Resolutions at the Annual General Meeting in Medivir on 4 May 2023LSE:0GP7Medivir Ab
2023/04/2716 : 06PR Newswire (US)MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2023LSE:0GP7Medivir Ab
2023/04/1716 : 30PR Newswire (US)Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combinationLSE:0GP7Medivir Ab
2023/04/0418 : 03PR Newswire (US)Medivir 2022 Annual Report publishedLSE:0GP7Medivir Ab
2023/03/3119 : 25PR Newswire (US)Notice of Annual General Meeting of Medivir AB (publ)LSE:0GP7Medivir Ab
2023/03/1717 : 01PR Newswire (US)Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACRLSE:0GP7Medivir Ab
2023/03/1417 : 18PR Newswire (US)First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima®LSE:0GP7Medivir Ab
2023/03/0900 : 08PR Newswire (US)Medivir to present at the Stockholm Corporate Finance Life Science DayLSE:0GP7Medivir Ab
2023/02/2317 : 03PR Newswire (US)Medivir to present at the Erik Penser Bank Healthcare DayLSE:0GP7Medivir Ab
2023/02/2117 : 54PR Newswire (US)Pia Baumann takes up her position as Chief Medical OfficerLSE:0GP7Medivir Ab
2023/02/2019 : 04PR Newswire (US)Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCCLSE:0GP7Medivir Ab
2023/02/1517 : 15PR Newswire (US)MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2022LSE:0GP7Medivir Ab
 Showing the most relevant articles for your search:LSE:0GP7

最近閲覧した銘柄

Delayed Upgrade Clock